Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 28;41(4):417–426. doi: 10.1097/ICO.0000000000002837

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

FIGURE 1. — A single TearCare treatment (BLACK, solid) and LipiFlow treatment (GRAY, dashed) were equivalent for the improvement in DED signs, TBUT, MGSS, corneal and conjunctival staining, and meibomian gland health. Panel A, TBUT (seconds) improved for both TearCare and LipiFlow at all study visits. Change from baseline TBUT was similar for both treatment groups. Panel B, MGSS improved for both TearCare and LipiFlow at all study visits. Change from baseline MGSS was similar for both treatment groups. Error bars represent standard deviation. Panel C, Mean total corneal staining (seconds) and mean conjunctival staining improved for both TearCare and LipiFlow at all study visits. Panel D, TearCare enabled equivalent improvements to overall meibomian gland health as measured by the number of meibomian glands yielding clear liquid and the number or meibomian glands yielding any liquid on manual expression of the glands.